Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its dominant cystic fibrosis portfolio into rare endocrine disorders. The deal provides access to Palsonify for acromegaly and a pipeline asset for congenital adrenal hyperplasia, potentially adding $5 billion in peak annual revenue. While the price is fair and strategically sound, results aren't expected until 2029, making it a long-term growth play for the biotech company.

07/10/2026, 4:05 AM • The Motley Fool

Moderna Stock Is Soaring. Is It Too Late to Buy?

Moderna's stock has more than doubled this year as the company transitions from a COVID-19 vaccine maker to a diversified biotech firm. With multiple late-stage vaccine programs (flu, norovirus, combination vaccines) and cancer therapies in development, the company is preparing for major product launches in 2027-2028. Strong financials including $7.5 billion in cash and improving revenue support long-term growth potential, though recent gains reflect high expectations and clinical risks remain.

07/07/2026, 5:15 AM • The Motley Fool

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More

Three biotech companies—Moderna, Revolution Medicines, and Axsome Therapeutics—significantly outperformed the S&P 500 in the first half of 2026 with double- and triple-digit gains. While Moderna faces expected pullback despite flu vaccine approval prospects, and Revolution Medicines shows modest upside, Wall Street expects Axsome to climb another 13% due to recent drug approvals and strong pipeline progress.

07/06/2026, 6:10 PM • The Motley Fool

Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?

The Fidelity MSCI Health Care Index ETF (FHLC) offers broad healthcare sector exposure with lower costs (0.08% expense ratio), higher dividend yield (1.3%), and lower volatility, making it suitable for conservative investors. The State Street SPDR S&P Biotech ETF (XBI) focuses on biotechnology with higher growth potential (89.3% 1-year return) but carries significantly higher risk (54% maximum drawdown) and costs (0.35% expense ratio), appealing to aggressive investors.

07/05/2026, 9:15 AM • The Motley Fool

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

Biogen announced a $1 billion acquisition of RayThera, a company with anti-inflammatory assets targeting immune-mediated conditions. This strategic move strengthens Biogen's immunology portfolio following its earlier acquisition of Apellis Pharmaceuticals. The company is successfully transitioning from its declining MS drug business to growth areas like Alzheimer's and rare diseases, with early signs of business stabilization and revenue growth.

07/04/2026, 4:02 AM • The Motley Fool

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

07/03/2026, 11:14 AM • The Motley Fool

Is Moderna Stock a No-Brainer Buy After a Key FDA Win?

Moderna received FDA advisory committee approval for its mRNA-based flu vaccine (mRNA-1010) for patients 50+, with potential FDA approval by August 5. The company also announced plans to develop an in vivo CAR-T candidate. However, despite a 150% surge over the past year and bullish sentiment, much of the comeback potential is already priced into the stock. With a $26.7 billion market cap while unprofitable, and the flu vaccine market estimated at only $9.5 billion, investors may want to wait for hype to fade before buying.

06/30/2026, 2:15 PM • The Motley Fool

Big Pharma Has a Case of Merger Mania

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

06/30/2026, 12:26 AM • The Motley Fool

Should You Buy Moderna Before Aug. 5?

Moderna's investigational flu vaccine candidate (mRNA-1010) received unanimous FDA advisory panel approval, with a regulatory decision expected by August 5. The stock has surged over 100% this year as the company reaches a key transition point with multiple product launches planned for 2027-2028. However, the analyst suggests waiting for a post-approval dip to buy, as much of the good news may already be priced in.

06/22/2026, 6:10 PM • The Motley Fool

Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?

Moderna's stock has surged over 100% this year as the company diversifies beyond COVID-19 vaccines using its mRNA platform. Key catalysts include FDA approval of mFlusiva (flu vaccine) expected August 5, 2026, and the European Commission's approval of mCOMBRIX (flu-COVID combination vaccine). The company's most transformative opportunity lies in cancer vaccines, with phase 3 data for mRNA-4157 expected later in 2026. Despite 260% revenue growth in Q1 2026, Moderna remains unprofitable but has $7.5 billion in cash and targets company-wide breakeven by 2028.

06/20/2026, 7:30 AM • The Motley Fool

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

Three stocks—Moderna, Krystal Biotech, and AMD—have significantly outperformed the S&P 500 this year and are positioned for continued growth. Moderna is advancing toward approvals for its influenza and norovirus vaccines plus cancer vaccine candidates. Krystal Biotech's gene therapy Vyjuvek for rare skin disease is generating strong earnings with expansion opportunities. AMD is capitalizing on AI growth through its server CPU leadership and gaining market share from Intel.

06/18/2026, 1:30 AM • The Motley Fool

FDA Panel Set To Debate Moderna Flu Shot

The FDA's VRBPAC panel will meet on June 18 to review Moderna's mRNA-based flu vaccine (mFlusiva/mRNA-1010) for adults 50 and older. The vaccine met all efficacy criteria in trials, but the panel will scrutinize the choice of standard-dose flu vaccine as a comparator and efficacy data limitations in older adults. Moderna seeks full approval for ages 50-64 and accelerated approval for 65+, with an FDA decision deadline of August 5.

06/17/2026, 8:23 AM • Benzinga

Stock Market Today, June 16: Nvidia, Broadcom, and Micron Technology Lead Drop in Nasdaq

The Nasdaq fell 1.15% on tech and chip weakness, with major semiconductor stocks like Nvidia, Broadcom, and Micron Technology declining due to profit-taking. The S&P 500 dropped 0.57%, while the Dow Jones rose 0.64% as investors rotated toward industrial, transportation, and financial sectors. CoreWeave surged nearly 10% on bullish analyst sentiment, while Robinhood Markets slid following layoff announcements. The Federal Reserve began its first meeting under new Chair Kevin Warsh.

06/16/2026, 5:24 PM • The Motley Fool

Dow Jones Hit Record Highs As Oil Drops To $77: Stock Market Today

U.S. stocks showed mixed performance on Tuesday as investors rotated out of technology into financials, utilities, and industrials. The Dow Jones reached record highs at 52,185.49, while the Nasdaq 100 declined 1.4%. Oil prices fell to $77/barrel on expectations of a Strait of Hormuz reopening deal. Federal Reserve Chair Kevin Warsh prepares for his first policy meeting with markets pricing in a 97% probability of unchanged rates.

06/16/2026, 1:12 PM • Benzinga

Moderna Strengthens Commercial Strategy As Pipeline Advances

Moderna announced organizational changes with President Stephen Hoge taking expanded oversight of R&D, manufacturing, and commercial operations. The company reported Q1 adjusted loss of $1.18 per share (better than expected) and revenue of $389 million (exceeding estimates). Moderna reiterated 2026 revenue growth guidance of up to 10% and expects potential launches of three new products in 2027-2028, including flu-COVID combination and norovirus vaccines. The company also anticipates key clinical milestones for its oncology and rare disease candidates.

06/16/2026, 12:56 PM • Benzinga